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Abstract 
We designed a prospective, randomized, open-label, blinded endpoint 
evaluation(PROBE) parallel group Phase 3b clinical trial comparing edoxaban (a new oral 
factor Xa inhibitor) with enoxaparin/warfarin followed by warfarin alone in subjects 
undergoing planned electrical cardioversion of non-valvular AF.  The primary efficacy 
endpoint is the composite endpoints of stroke, systemic embolic event (SEE), myocardial 
infarction (MI) and cardiovascular (CV) mortality, from randomization until the end of 
follow-up (Day 56 post cardioversion).  The primary safety endpoint is the composite of 
major and clinically-relevant non-major (CRNM) bleeding, from the first administration 
of study drug to end of treatment (Day 28 post cardioversion) + 3 days.  The primary 
efficacy analysis will be conducted on the intention-to-treat population whereas the 
primary safety analysis – on the safety population (refer to definitions in the main text). 
The study includes stratification on the following levels: (i) approach to cardioversion 
(transoesophagel echocardiography (TEE) or non-TEE) as determined by the 
Investigator; (ii) subject’s experience in taking anticoagulants at the time of 
randomization (anticoagulant-experienced or anticoagulant-naïve); and (iii) assigned 
edoxaban dose (full 60 mg QD or reduced 30 mg dose QD). A subject with one or more 
factors (CrCl ≥ 15mL/min and ≤ 50 mL/min, low body weight [≤ 60 kg], and concomitant 
use of p-pg inhibitors (excluding amiodarone) will receive a reduced dose (30 mg) of 
edoxaban if the subject is randomized to the edoxaban group.  
ENSURE-AF will be the largest prospective randomised trial of anticoagulation for 
cardioversion, also involving a NOAC, edoxaban. 
 
Key words:  edoxaban, cardioversion, atrial fibrillation, warfarin 
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Introduction 
For over 50 years warfarin-based anticoagulation has been the pharmacologic approach 
to reducing thromboembolic risk in this setting.  Randomized controlled studies have 
shown that warfarin, the most commonly used vitamin K antagonist (VKA), reduces the 
risk of ischemic stroke in patients with AF by two-thirds.   The VKAs have various 
limitations and based on these challenges, only two-thirds of patients eligible for 
warfarin therapy actually receive treatment1.  Furthermore, among patients who receive 
warfarin in preparation for cardioversion, major hemorrhagic complications (defined as 
complications requiring hospitalization, blood transfusion, or urgent surgery) are 
reported in 1% to 2% of patients during the first month of therapy2 3. Also, the use of 
warfarin as an anticoagulation strategy for cardioversion can result in procedure 
cancellations due to subtherapeutic INRs 4. 
 
The landscape for stroke prevention in atrial fibrillation (AF) has changed with the 
availability of the Non-VKA Oral Anticoagulants (NOACs), which offer relative efficacy, 
safety and convenience compared to the VKAs.  In a recent meta-analysis by Ruff et al5, 
the NOACs significantly reduced stroke or systemic embolic events by 19% compared 
with warfarin (RR 0.81, 95% CI 0.73–0.91; p<0.0001), mainly driven by a reduction in 
hemorrhagic stroke (0.49, 0.38–0.64; p<0.0001).  NOACs also significantly reduced all-
cause mortality (0.90, 0.85–0.95; p=0.0003) and intracranial hemorrhage (0.48, 0.39–
0.59; p<0.0001), but increased gastrointestinal bleeding (1.25, 1.01–1.55; p=0.04).   
 
Cardioversion and thromboembolism 
  Cardioversion (both electrical and pharmacological) in patients with AF is associated 
with an increased risk of thromboembolic events6-8.   The risk is higher (5% to 7%) if 
anticoagulation is inadequate or absent2,9.  With adequate anticoagulation, the risk of 
thromboembolic events in the periprocedural period is in the range of 0.7% to 0.8%.10   
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Rates of thromboembolism from observational studies and post-hoc subgroup analyses 
from clinical trials are summarised in Table 111-14 15.  
The use and duration of anticoagulation in the setting of cardioversion has undergone 
limited evaluation in randomized prospective trials.   Based on the observational data 
current recommendations for patients with AF of > 48 hours duration is therapeutic 
anticoagulation for at least 3 weeks before and 4 weeks after cardioversion regardless 
of stroke risk.   Following cardioversion for AF of any duration, the decision regarding 
long-term anticoagulation therapy should ultimately be based on the thromboembolic 
risk profile, rather than the presence of sinus rhythm. 
TEE-guided Cardioversion 
The Assessment of Cardioversion Using Transesophageal  Echocardiography (ACUTE) 
study including 1222 subjects demonstrated comparable risk of thromboembolic events 
with both the conventional strategy of 3 weeks of warfarin before cardioversion and the 
TEE-guided strategy of short-term anticoagulation with intravenous (IV) unfractionated 
heparin or warfarin just prior to cardioversion (0.5% and 0.8%, respectively; p = 0.50)3. 
The TEE-guided group in the ACUTE study had a significantly lower risk of bleeding in the 
pericardioversion period compared with the conventional group (2.9% versus 5.5%; 
p = 0.03) which was probably related to the longer total duration of anticoagulation in 
the conventional group.  The absence of left atrial thrombus on TEE does not preclude 
the need for anticoagulation just before and during cardioversion as well as 
continuation for at least 4 weeks after the procedure16.  Finally, it should be 
acknowledged that the ACUTE study was discontinued prematurely due to problems 
with recruitment and statistically it was substantially underpowered for non-
equivalence.  Despite this important limitation, its results were incorporated in current 
guideline recommendations.  
Use of Non-VKA Oral Anticoagulants (NOACs) 
Major drawbacks of VKAs such as warfarin in the setting of cardioversion are its delayed 
onset of action.  In addition, fluctuations of INR during the pre-cardioversion period or 
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on the day of cardioversion may lead to cancellation of the procedure with 
inconvenience and additional costs for both the patient and the health care system.  
The availability of new rapid onset anticoagulants such as dabigatran (a direct thrombin 
inhibitor), apixaban and rivaroxaban (FXa inhibitors) may potentially avoid the 
therapeutic delay observed with warfarin.    
A post-hoc analysis of subjects undergoing cardioversion in the Randomized Evaluation 
in Long-Term Anticoagulation Study (RE-LY) study demonstrated comparability of 
dabigatran etexilate to warfarin in the incidence of stroke or major bleeding within 
30 days of cardioversion17.3 In the rivaroxaban versus warfarin in patients with 
nonvalvular AF who were at moderate to high risk for stroke (ROCKET AF) study, there 
was no significant difference between those treated with rivaroxaban or warfarin in 
stroke or systemic embolism in subjects undergoing rhythm control (including electrical 
or pharmacological cardioversion)18. One small (743 cardioversions performed in 540 
patients) post-hoc analysis of patients undergoing cardioversion in the ARISTOTLE trial 
has been published15.   In this analysis, no stroke or systemic emboli occurred in the 30-
day follow-up period, whilst major bleeding occurred in 1 patient (0.2%) receiving 
warfarin and 1 patient receiving apixaban (0.3%).   
Only one prospective randomized trial of a NOAC in the cardioversion setting is has 
been published. The X-VERT trial19 studied 1504 AF patients undergoing cardioversion 
who were randomized 2:1 (rivaroxaban:VKA) using 2 cardioversion strategies: (i) the 
first approach is ‘early cardioversion’ with the pre-cardioversion anticoagulation goal of 
1 to 5 days using rivaroxaban or usual therapy (heparin + VKA), and (ii) the alternative 
approach of ‘delayed cardioversion’, with either rivaroxaban or VKA being administered 
for 21 to 56 days before cardioversion.  The primary efficacy outcome occurred in 0.51% 
in the rivaroxaban group and 1.02% in the VKA group [risk ratio 0.50; 95% confidence 
interval (CI) 0.15–1.73]. Major bleeding occurred in 0.6% patiens in the rivaroxaban 
group and 0.8% in the VKA group (risk ratio 0.76; 95% CI 0.21–2.67). The present 
cardioversion study with edoxaban (ENSURE-AF) is the largest cardioversion trial to be 
conducted to date, which addresses the gap in knowledge of management of patients 
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with AF who are at low risk of thromboembolic complications and are candidates for 
rhythm control.  
 
Edoxaban  
Edoxaban is an orally active, selective, direct and reversible inhibitor of Factor Xa (FXa). 
Peak plasma concentrations of edoxaban occur at 1 to 2 hours after dosing with steady-
state achieved after three days of QD dosing (study U-151)20; hence, it could offer a 
safer, more effective, and easily managed oral anticoagulant agent for use in the 
pericardioversion setting.    
Edoxaban has been investigated for the following indications: (i) the prevention of 
venous thromboembolic event (VTE) in subjects undergoing total knee replacement, 
total hip replacement, and hip fracture surgery21,22;  (ii) the reduction of the risk of 
stroke and systemic embolic event (SEE) in subjects with atrial fibrillation (ENGAGE AF-
TIMI 48 study)23; and (iii) the treatment of acute VTE and prevention of recurrence in 
subjects with acute symptomatic deep vein thrombosis and /or pulmonary embolism 
(PE) (Hokusai-VTE) 24. 
 
ENSURE-AF Study design [ClinicalTrials.gov Identifier: NCT02072434] 
We designed a prospective, randomized, open-label, blinded endpoint evaluation 
(PROBE) parallel group study in subjects with confirmed ongoing AF of no longer than 12 
months and in whom electrical cardioversion is planned.   
This study is designed to compare the incidence of the composite endpoints of stroke, 
SEE, myocardial infarction (MI) and CV death and to compare the incidence of major and 
clinically relevant non-major (CRNM) bleedings after TEE or non-TEE-guided electrical 
cardioversion in the edoxaban arm versus the enoxaparin/warfarin arm. Composite 
endpoints of the key efficacy and safety parameters will also be tested. 
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This study will be conducted in compliance with the protocol, the ethical principles as 
outlined in the Declaration of Helsinki, the International Conference on Harmonization 
(ICH) consolidated Guideline E6 for Good Clinical Practice (GCP) (CPMP/ICH/135/95), 
and applicable regulatory requirement(s). 
 
Study Population 
This study will enroll subjects with documented AF for at least 48 hours but ≤ 12 months 
and who are planned for electrical cardioversion and anticoagulation therapy.  Subjects 
who are receiving or have received prior anticoagulant and/or antiplatelet therapies are 
eligible, as well as subjects who are naive to anticoagulant and/or antiplatelet therapy. 
Inclusion and Exclusion criteria are shown in webonly Table w1. 
Efficacy and safety endpoints 
Trial endpoints are summarized in Table 2. 
The primary efficacy objective of this study is to compare the incidences of the 
composite endpoints of stroke, SEE, MI and CV mortality between the edoxaban group 
and the enoxaparin/warfarin group from randomization to end of follow up (FU). 
The primary safety objective of this study is to compare the incidence of the composite 
endpoints of major and CRNM bleeding between the edoxaban group and the 
enoxaparin/warfarin group from the first administration of study drug to end of 
treatment + 3 days. 
The secondary objective of this study is to compare the incidences of the composite 
endpoints of stroke, SEE, MI, CV mortality and major bleedings between the edoxaban 
group and the enoxaparin/warfarin group from randomization to end of follow up. 
 
Exploratory objectives of this study are shown in webonly Table w2.  
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Stratification 
The stratification in the study will be performed on the following levels: 
• approach to cardioversion (TEE or non-TEE) as determined by the Investigator; 
• subject’s prior experience in taking anticoagulants at the time of randomization (i.e. 
anticoagulant-experienced or anticoagulant-naïve); 
• selected edoxaban dose (full 60 mg or reduced 30 mg dose). A subject with one or 
more factors (CrCL ≥ 15mL/min and ≤ 50 mL/min, low body weight [≤ 60 kg], and 
concomitant use of p-pg inhibitors (excluding amiodarone) will receive the reduced dose 
(30 mg) of edoxaban if the subject is randomized to the edoxaban group.     During the 
course of the study treatment period, if the subject’s CrCl falls between ≤ 50 mL/min 
and ≥ 15 mL/min (confirmed by repeat measurement at least one week apart) and the 
CrCl change is > 20% of the subject’s baseline CrCl, the edoxaban dosage will be reduced 
to 30 mg permanently until the end of the study treatment period, even if the subject 
subsequently experiences improved CrCl to > 50 mL/min.   
Similarly, during the course of the study, if the subject’s body weight drops to ≤ 60 kg 
(confirmed by repeat measurement at least one week apart) and the body weight 
change is > 10% of the subject’s baseline body weight, the edoxaban dosage regimen 
will be reduced to 30 mg permanently, even if the subject subsequently regains weight 
to > 60 kg.     
Subjects on concomitant P-gp inhibitors (with the exception of amiodarone) with the 
study drug at the time of randomization will be dose reduced to 30 mg.  Post 
randomization, the edoxaban dosage will be reduced by half (60 mg QD to 30 mg QD) at 
any time that the subject is concomitantly taking one or more of the P-gp inhibitors 
(again, excluding amiodarone).  Conversely, the edoxaban dosage will be returned to the 
regular dosage of 60 mg QD any time the subject is not taking the concomitant 
medication.   
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Subjects will be randomized in a 1:1 ratio to two treatment groups within each stratum 
based on a computer-generated randomization schedule generated prior to study start.  
Enrollment will be managed to achieve the balance of treatment assignment within 
each stratum.  Recruitment will continue until at least 1000 subjects in each arm have 
undergone cardioversion (spontaneous or electric).  
 
Insert Figure 1 
 
1. TEE-guided Stratum 
Warfarin arm:  
On the day of randomization (Day -3), subjects assigned to this arm will either be: 
a) Naive to anticoagulation or have been taking VKA but have a sub-therapeutic INR 
(<2.0) or have been taking anticoagulants other than VKA (e.g. NOAC or 
parenteral anticoagulants); 
b) Have been taking anticoagulants and have an INR ≥2 at the time of 
randomization. 
Subjects in category a) will start treatment with a minimum of 1 dose each of 
enoxaparin and warfarin on the day of randomization and these drugs will be continued 
until INR ≥2 has been obtained. After a therapeutic range (TR) is achieved, subjects will 
discontinue enoxaparin and continue warfarin until end of treatment (Day 28 following 
the procedure). 
Subjects in category b) will not require enoxaparin and will start treatment with warfarin 
alone. If INR is >3 at randomisation, the dose of warfarin in the study will be adjusted to 
achieve and maintain the therapeutic INR level of 2.0-3.0.   
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 10 
In both categories within the first several days from the start of warfarin treatment, INR 
measurements will be conducted with a frequency of once every 2-3 days until the value 
reaches the TR; thereafter subjects will attend the planned study visits but may have ad 
hoc INR checks as deemed necessary by the Investigator.  
Both TEE and cardioversion may be performed on the same day of randomization 
providing that the subject has either received at least 1 dose of enoxaparin or for those 
patients not requiring enoxaparin at randomization, that the patients INR is in TR (2.0-
3.0). In any case, the cardioversion procedure has to be performed within a maximum of 
3 days from randomization.  
If no thrombi are identified in the atria by TEE, electrical cardioversion will be conducted 
and subjects will continue on enoxaparin (if started from randomization) and warfarin 
until their INR reaches the TR. In both categories it will be important to achieve the TR 
of warfarin within 8 days after randomization and to maintain the TR during the study 
treatment period.  Enoxaparin given beyond 14 days of treatment will trigger automatic 
notification of the Sponsor. 
 
Edoxaban arm:  
On the day of randomization, subjects will start treatment with edoxaban and continue 
treatment until day of TEE/cardioversion (Day 0).  If the subject transitions from a prior 
anticoagulant to edoxaban, this will be done in accordance with the transition algorithm 
provided in webonly Table 3 (that is, either discontinue VKA and start edoxaban when 
INR is ≤2.5 or for NOACs or parenteral anticoagulants (e.g. low molecular weight 
heparins) start edoxaban when the next dose of the NOAC/parenteral anticoagulants is 
due (note that for unfractionated heparin (UFH) start edoxaban 4 hours after the last 
dose of UFH). Both TEE and cardioversion may be performed on the same day but 
cardioversion has to be performed within a maximum of 3 days from randomization.   
The next dose of edoxaban will be taken the day after cardioversion and then continued 
on a 24-hour cycle.   
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If no thrombi are identified in the atria by TEE, electrical cardioversion will be conducted 
and the subject will continue with edoxaban until Day 28 following the procedure.   
 
Follow-up 
All subjects will be followed for safety for 30 days (Day 58) after completing treatment 
with warfarin or edoxaban in the respective arms. If thrombi are identified during the 
TEE procedure, the subject will not be eligible for subsequent cardioversion and may be 
discontinued from treatment (but the subject will continue to participate in the study 
including the follow-up period).  The Investigators will be encouraged to continue 
treatment with the drug to which the subject was randomized and repeat the TEE on 
Day 28 to assess progress of the thrombus.  This information will be collected in details 
from the sites and will be further analyzed. A repeat TEE is not mandatory for 
continuation in the study.   
Subjects with unsuccessful cardioversion or relapse of AF may be cardioverted again at 
the Investigator’s discretion; however, duration of treatment in the study will be 
calculated based on the initial cardioversion date.  These subjects will be encouraged to 
remain in the study and continue the study treatment as per the protocol. 
 
2.  Non-TEE-guided Stratum 
Warfarin arm: Subjects assigned to this arm will either: 
a) Have taken VKA prior to randomization and have an INR ≥2 on the day of 
randomization; 
b) Have sub-therapeutic INR at randomization (<2), have taken an anticoagulant 
other than VKA (e.g. NOAC or parenteral anticoagulants) or are anticoagulant-
naïve. 
The following algorithms will be implemented: 
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Subjects in category a) will not require enoxaparin and will start 21 days of warfarin 
anticoagulation from the day of randomization (Day -21). If INR in the subject is >3 at 
randomization, the dose of warfarin in the study will be adjusted to achieve and 
maintain the therapeutic INR level of 2.0-3.0.   
Subjects in category b) will receive enoxaparin and daily warfarin until the INR is ≥2.0.  
At this time, enoxaparin will be discontinued and warfarin continued for a total of 21 
days. 
In both categories within the first several days from the start of warfarin treatment, INR 
measurements will be conducted with a frequency of once every 2-3 days until the value 
reaches the TR; thereafter subjects will attend the planned study visits but may have ad 
hoc INR checks as deemed necessary by the Investigator. 
For all subjects, cardioversion will be performed on Day 0, which will occur at a 
minimum of 21 days following the start of treatment with the study drug or within 3 
days thereafter.   
Webonly Table w3 summarizes the guidance of patient management in accordance with 
the INR value before and on the day of cardioversion. In subjects who do not have a TR 
INR (2.0-3.0) on the day of randomization, it will be important to achieve a TR of 
warfarin within 8 days after randomization and to maintain the TR during the study 
treatment period.  
 
Edoxaban arm:  
After randomization into this stratum, subjects will receive edoxaban for 21 days before 
cardioversion followed by cardioversion on Day 0 (or within 3 days thereafter) and an 
additional 28 days of edoxaban treatment starting from the day of cardioversion.  
If the subject transitions from a prior anticoagulant to edoxaban, this will be completed 
in accordance with the transition algorithm provided in webonly Table w4 (that is, for 
VKA discontinue the drug and start edoxaban when INR is ≤2.5; for NOAC users, start 
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edoxaban when the next dose of the NOAC is due or for parenteral anticoagulants start 
edoxaban when the next dose of the anticoagulant is due with the exception of UFH 
where the first dose of edoxaban will be 4 hours after the last dose of UFH). The count 
of 21 days will start from the day of the first dose of edoxaban. 
 
Both arms:  
All subjects will be followed for safety for 30 days (Day 58) after completing treatment 
with warfarin or edoxaban in both arms. 
Subjects with unsuccessful cardioversion or relapse of AF may be cardioverted again at 
the Investigator’s discretion; however, duration of treatment in the study will be 
calculated based on the initial cardioversion date.  These subjects will be encouraged to 
remain in the study and continue the study treatment as per the protocol.   
All subjects with a CHA2DS2-VASc (or CHADS2) score ≥2 and subjects with CHA2DS2-VASc 
score =1 (when the use of oral anticoagulants is preferred over aspirin) will require to be 
transitioned at the end of the study treatment to a standard-of-care anticoagulant in 
accordance with the current European and US guidelines on the anticoagulant 
treatment of patients with AF. These subjects will be transitioned to the treatment 
chosen by the Investigator and strictly in accordance with the transition algorithms 
provided in webonly Table w3.   
Subjects with spontaneous cardioversion in the pre-procedural period (confirmed by a 
recording of sinus rhythm) will still need to complete 28 days of treatment from the day 
that spontaneous cardioversion was noted and 30 days of follow-up (58 days in total). 
 
Trial conduct 
The estimated duration of the trial is 18 months, and approximately 284 study sites in 
20 countries in Europe and North America will be used. 
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Planned sample size 
2200 subjects are planned to be randomized into the study (1100 per treatment arm) to 
achieve at least 2000 electrical or spontaneous cardioversions. Based on the post hoc 
analyses of the Cardioversion population in the RE-LY study the event rate in the 
warfarin group is 0.8% of stroke/SEE and 1.7% of major bleeding during the 30 days post 
cardioversion. Event rates in other cardioversion studies are even lower. Therefore a 
formal sample size determination based on non-inferiority or superiority of edoxaban 
versus warfarin is not feasible with the anticipated low event rate and an adequately 
powered study would require a sample size of over ten thousand patients.  The study 
will be sized with an appropriate number of subjects that will provide an estimate of 
incidence of primary efficacy or primary safety endpoints.  Assuming an incidence rate 
of the combined efficacy endpoint of 0.6% in both groups, 1000 electrically or 
spontaneously cardioverted subjects in each treatment group will provide a 95% 
confidence interval (CI) around the point estimate of the difference of -0.68% to 0.68%. 
 
Study Organization 
An Independent Data Monitoring Committee (IDMC) will be created to further protect 
the rights, safety, and well-being of subjects who will be participating in this study by 
monitoring their progress and results.  The IDMC will comprise of qualified scientists, 
who are not Investigators in the study and not otherwise directly associated with the 
Sponsor.   The IDMC will monitor data during the study, and can recommend study or 
treatment regimen/group termination to the Study Oversight Committee. 
An independent study specific Clinical Events Committee (CEC) will review and 
adjudicate key endpoint events (all deaths, suspected strokes/TIAs, suspected SEEs, 
suspected MIs, and overt bleeding events that require medical attention, liver enzyme 
abnormalities requiring study drug discontinuation) without unblinding (including all 
suspected clinical endpoint events from subjects who permanently discontinued study 
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drug).   The CEC will comprise qualified judges, who are not Investigators in the study 
and not otherwise directly associated with the Sponsor.  The CEC judges will remain 
blinded to treatment throughout the adjudication process and the study.  The 
CEC-adjudicated data will be used in the final efficacy and safety analyses.    
The Study Executive Committee will be responsible for the overall design, conduct, and 
supervision of the study, including the development of any protocol amendments.  It 
will adjudicate policy among the various constituencies of the study, and will be 
responsible for reviewing the progress of the study at regular intervals to ensure subject 
safety and study integrity.  The Study Executive Committee has the authority to 
terminate the study or treatment regimen/group based on recommendations from the 
IDMC. 
An ENSURE-AF Study Steering Committee will be created to provide clinical guidance on 
study implementation and conduct of the study, and interpretation of results.  It will 
consist of national lead investigators from the countries participating in the study as 
well as designated Sponsor and CRO members. 
The study is funded by Daiichi Sankyo Development Ltd. and Daiichi Sankyo Pharma 
Development. The authors are solely responsible for the design and conduct of this 
study, all study analyses, the drafting and editing of the paper and its final contents.  
 
Conclusion 
In summary, ENSURE-AF is a prospective, randomized, open-label, blinded endpoint 
evaluation (PROBE) parallel group Phase 3b clinical trial comparing edoxaban with 
enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned 
electrical cardioversion of non-valvular AF, and will be the largest prospective 
randomized trial comparing a NOAC (edoxaban) against warfarin for efficacy and safety 
in the peri-cardioversion period.    
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Table 1. Rates of thromboembolism from observational studies, post-hoc subgroup 
analyses from clinical trials and a prospective study 
 
 Ref n % thromboembolism 
on anticoagulation 
with warfarin (vs 
other anticoagulant, if 
relevant) 
n % 
thromboembolism 
with no warfarin 
(i) Observational 
studies 
     
Rokseth  1963  15 274 1.6   
Bjerklund  1969 16 186 1.1 162 6.8 
Weinberg  1989 2 51 0 28 7.1 
Arnold  1992 9 52 0 115 6.3 
Klein    3 54 1.6   
Morris 1964 13   66 4.5 
Roy 1986 
 
14   42 4.8 
(ii) Posthoc 
analyses from 
trial cohorts 
Ref n N (%) 
thromboembolism 
on anticoagulation 
with warfarin  
n N (%) 
thromboembolism 
with NOAC 
ROCKET-AF1 31 161 Stroke/SEE: 3 
CVM: 4 
160 Stroke/SEE: 3 
CVM: 2 
RE-LY 17 664 Stroke/SEE: 
 4 (0.6) 
647 
(D110) 
672 
(D150) 
Stroke/SEE: 
5 (0.8 – D110) 
2 (0.3 – D150) 
ARISTOTLE 15 275 Stroke/SEE: 0 
MI: 1 (0.2) 
265 Stroke/SEE: 0 
MI: 1 (0.2) 
(iii) Prospective 
study  
Ref n N (%) 
thromboembolism 
on anticoagulation 
with warfarin  
n N (%) 
thromboembolism 
with NOAC 
X-VERT 19 1504 1.02 78 0.51 
1Analysis included patients both with ablation and cardioversion 
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Table 2.  
Study Endpoints: Efficacy endpoints 
 Stroke, SEE, MI and CV mortality; 
 All-cause mortality. 
Safety endpoints 
 Major and CRNM bleedings 
 All bleedings. 
Net clinical outcomes 
 Stroke, SEE, MI, all-cause mortality and life-
threatening bleed; 
 Stroke, SEE, MI and Major bleed; 
 Stroke, SEE, MI, Major bleed, and all-cause 
mortality; 
 Disabling or fatal stroke, Fatal SEE, Fatal MI and 
Life-threatening or fatal bleed; 
 Disabling or fatal stroke, Fatal SEE, Fatal MI, Life-
threatening or fatal bleed, and CV mortality; 
 Disabling or fatal stroke, Fatal SEE, Fatal MI, Life-
threatening or fatal bleed, and all-cause mortality; 
Other endpoints 
 Proportion of successful cardioversion and sinus 
rhythm maintenance 
 Incidence and time to first AF recurrence 
 Satisfaction with anticoagulation therapy as 
assessed by the PACT-Q2 questionnaire and EHRA 
score assessment  
 Number of hospital admissions, reason for 
hospitalization, length of stay and ward type (eg, 
intensive care unit, general ward, etc.) for all 
causes  
 Number of subject visits to the investigational site 
throughout the study 
 Number of hospital re-admissions for all causes 
 Number of days from randomization to electrical 
cardioversion in the non-TEE-guided stratum 
 Number of subjects out of therapeutic INR range 
during pre- and post-cardioversion period in the 
warfarin arm 
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Figure 1  
(a) Study Flow Diagram for TEE-Guided Stratum 
 
 
CVN=Cardioversion; TEE= Transesophageal Echocardiography 
 
(b) Study Flow Diagram for Non-TEE-Guided Stratum 
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